Targeting the glabellar frown lines with OnabotulinumtoxinA: In-silico evidence supporting concentrated, low-volume...

Area of Science:

• Aesthetics and Cosmetic Science
• Computational Biology and Bioinformatics
• Pharmacology and Toxicology

Background:

• Conventional low-dose, high-volume Botulinum Neurotoxin Type A (BoNT-A) protocols for glabellar frown lines exhibit limited durability and diffusion control.
• Optimizing BoNT-A delivery is crucial for enhancing treatment outcomes and patient satisfaction in aesthetic medicine.

Purpose of the Study:

• To evaluate high-dose, low-volume BoNT-A glabellar injection strategies using an in silico framework.
• To mechanistically simulate dose-volume interactions and predict treatment efficacy and duration.
• To explore personalized dosing algorithms based on patient-specific factors.

Main Methods:

• Development of a multiscale, in silico framework integrating finite element modeling of anisotropic tissue diffusion.
• Incorporation of receptor-specific pharmacokinetics/pharmacodynamics (PK/PD) and machine learning for off-target risk prediction.
• Simulation using a synthetic cohort of 20,000 virtual patients with anatomically realistic facial conditions.

Main Results:

• Reduced-volume, concentrated BoNT-A dosing significantly enhances SV2 receptor occupancy (up to 93.7%).
• Toxin diffusion is confined within target musculature, prolonging clinical duration to an average of 124.7 days.
• A 30-70% variance in BoNT-A exposure and efficacy was observed between fixed-dose and weight-adjusted regimens.

Conclusions:

• High-dose, low-volume BoNT-A injection strategies offer enhanced efficacy, durability, and diffusion control compared to conventional methods.
• The study establishes a data-driven rationale for precision-targeted toxin administration and personalized dosing.
• Clinical validation is required to confirm the translatability of these in silico findings.